Hemacare Corp (HEMA) 0.6400 $HEMA HemaCare Atte
Post# of 273318
Posted On: 06/09/2016 5:12:01 AM
Hemacare Corp (HEMA) 0.6400 $HEMA
HemaCare Attends BIO 2016 and Stem Cell Research Meetings
BusinessWire - Tue May 31, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending two key conferences during the month of June in San Francisco. The first conference, BIO International Convention (BIO), held June 6-9th at the Moscone Center, draws over 15,000 biotechnology and pharma leaders together for a week of intensive networking and partnering to discover new opportunities in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy, a focus critical to HemaCare. The International Society of Stem Cell Research (ISSCR) will be conducted June 22nd-25th, also at the Moscone Center. This meeting is the premiere gathering of research and development scientists, to share and collaborate on advancements in stem cell therapies and treatments. HemaCare is actively expanding its capabilities in support of stem cell research based on increased demand for our portfolio of stem-cell enriched, mobilized peripheral blood and bone marrow-derived primary cells.
HemaCare Attends Cell Therapy Meeting in Singapore
BusinessWire - Mon May 23, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending the ISCT meeting May 25-28th at the Suntec Convention and Exhibit Centre in Singapore, to support the society's annual gathering of clinicians, regulators, researchers and other industry partners, whose objective is to translate cellular therapy into safe and effective treatments to improve patient's lives. This is the first time the ISCT is conducting its annual meeting in Asia, and consequently, there will be added focus on current and future developments of cell therapy delivery and commercialization in Asia, a region where HemaCare has recently expanded through distribution partners. HemaCare will also present a poster session to highlight its core competencies for supplying highly pure and viable human hematopoietic stem cells and mature primary cells in global demand by these investigators.
HemaCare Signs Distribution Agreement with China-Based Partner
BusinessWire - Thu May 12, 3:11PM CDT
HemaCare Corporation, (OTCBB: HEMA) a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in China with Shanghai-based MT-Biological Science and Technology Co. Ltd. This partnership ensures researchers in China can access HemaCare's human healthy and disease state cryopreserved hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support.
HemaCare Attends the American Association of Cancer Research Annual Meeting
BusinessWire - Wed Apr 13, 7:00AM CDT
HemaCare Corporation, (OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending the AACR annual meeting at the Ernest R. Morial Convention Center in New Orleans, Louisiana, to support and learn the latest advances by cancer researchers. The meeting is host to over 16,000 scientific and clinical researchers and patient advocacy groups that focus on translating the mechanisms of cancer pathologies into viable bedside diagnostics and treatments. HemaCare will conduct educational presentations at its booth to increase awareness of its ever expanding capabilities for supplying highly pure and viable human hematopoietic stem cells and mature primary cells in demand by these investigators.
HemaCare Reports Strong 2015 Results
BusinessWire - Mon Apr 11, 7:00AM CDT
HemaCare Corporation, (OTCBB:HEMA) today reported financial results for 2015, showing strong gains in both revenue and gross profit margins compared to the prior year. For the full year, revenue from continuing operations more than doubled to $9.7 million, while gross profit margin rose to 45% from 27%. Loss from continuing operations narrowed to $1.38 million from $4.75 million, and after a gain from the sale of the Company's Therapeutic Apheresis business, 2015 net income totaled $3.24 million.
HemaCare Expands Its Offering of Stem Cell-Enriched Peripheral Blood
BusinessWire - Mon Mar 28, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it has expanded its offering of stem cell rich peripheral blood through the addition of a new protocol. This type of blood, referred to among researchers as "mobilized peripheral blood," is collected following a procedure that induces the bone marrow to produce more white cells into the periphery. These white cells can then be collected with a routine leukapheresis and provided to researchers within 24 hours. The most widely studied cell populations within these collections are CD34+ stem cells. These cells are used by investigators to study the mechanism of, and develop therapies for, diseases such as cancer, inflammatory conditions like arthritis and immune deficiency-based pathologies such as HIV. Additionally, this type of premium research material is a critical component to advancing research from the bench into potential clinical trials.
HemaCare to Increase Bone Marrow Capability
BusinessWire - Mon Mar 21, 7:00AM CDT
HemaCare Corporation (OTC:HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it has expanded its capabilities to offer stem cell rich bone marrow products by increasing its donor recruitment efforts and internal collection capacity in the Los Angeles, California, area under the direct supervision of its Medical Director. HemaCare's bone marrow portfolio, which includes unprocessed bone marrow, as well as highly purified isolated cell populations, is in high demand globally and a critical component in regenerative medicine research.
HemaCare to Present at Phacilitate Cell & Gene Therapy World 2016
BusinessWire - Wed Jan 13, 1:47PM CST
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, today announced that Lou Juliano, Senior Vice President of Global Sales and Business Development, will present recent findings by HemaCare's research group on the sustainability of freshly isolated leukopaks (apheresis-derived white blood cells) when cryopreserved and shipped around the world for use in cell therapy applications. The results described in this presentation are of key importance to cell therapy researchers, who depend on HemaCare as a source for highly pure, viable, and functional cells to develop their therapies. Additionally, HemaCare will host a roundtable discussion on the importance of donor selection and management when used for the development of allogeneic cell therapies. This discussion will be critical to cell therapy companies who look to develop allogeneic "off-the-shelf" therapies that can treat multiple patients with engineered, cost-effective cancer treatments.
HemaCare Signs Strategic Global Distribution Agreements
BusinessWire - Mon Dec 07, 7:00AM CST
HemaCare Corporation, a leader in cell and tissue collection, processing, and autologous and allogeneic cell therapy solutions, has expanded its global capabilities through strategic distribution agreements in North America, Europe and Asia. These partnerships ensure researchers around the globe can access HemaCare's human healthy and disease state, fresh or frozen, hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support.
HemaCare to Support Key Cell Therapy Conferences Through Sponsorship and Technical Presentations
BusinessWire - Mon Nov 02, 7:00AM CST
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, will present at two of the most important meetings in cellular and immune-therapy this month. Each presentation will focus on HemaCare's expertise in preserving hematopoietic cells for use by researchers and developers of immunotherapy.
HemaCare Committed to Cell Therapy Research Through Strategic Agreements
BusinessWire - Mon Oct 19, 7:00AM CDT
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, has expanded its growing cell therapy client portfolio through several supply agreements with Cellectis, Dendreon, and Sotio. Under the agreements, HemaCare provides process development support and supplies high-quality cGMP and research-grade biological material for use in cell therapy research and development of commercially available products, including Provenge(R).
HemaCare to Sponsor Phacilitate Cell & Gene Therapy Meeting Series
BusinessWire - Mon Sep 28, 7:00AM CDT
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, today announced a two-year, multi-event sponsorship of the Phacilitate Cell & Gene Therapy Forums. Considered the largest gathering of cell and gene therapy experts in the world, Cell & Gene Therapy Forums draw leaders from the pharma and biotech communities interested in the latest innovations in cell therapy.
Apheresis (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) Markets Report - Global Forecast to 2020
M2 - Mon Sep 28, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/392dth/apheresis_market) has announced the addition of the "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis), Procedure (Therapeutic Apheresis, Donor Apheresis/Apheresis Blood Donation), Technology & by Product - Global Forecast to 2020" report to their offering. The global apheresis market is expected to reach USD 2.5 Billion by 2020, growing at a CAGR of 11.2% during the forecast period (2015 to 2020) The market is mainly driven by the rising incidences of blood disorders and chronic diseases, increasing demand for source plasma from biopharmaceutical companies, and increasing demand for blood for transfusion in surgical procedures and accident & trauma cases. In this report, the apheresis market is segmented by procedure, product, technology, application, and region. The apheresis market, by procedure, is mainly segmented into automated blood collection and therapeutic apheresis. In 2014, the automated blood collection segment accounted for the largest share of approximately 77.2% of the market, and is expected to grow at a CAGR of 10.7% during the forecast period. Growth in this segment is mainly attributed to the increasing severity of blood shortage and growing concern regarding blood safety, and increasing incidences of blood disorders and chronic diseases. On the basis of applications, the market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, LDL apheresis, and others (photopheresis, lymphapheresis, and extracorporeal immunoadsorption). The plasmapheresis segment accounted for the largest share 46.5% of the global apheresis market in 2014. The large share of plasmapheresis is attributed to the increasing demand of source plasma for transfusion from hospitals and for fractionation from biopharmaceutical companies. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Apheresis Market, By Procedure 8 Global Apheresis Market, By Product 9 Global Apheresis Market, By Technology 10 Global Apheresis Market, By Application 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Group) - B. Braun Melsungen AG - Cerus Corporation - Fresenius Se & Co. KGAA - Haemonetics Corporation - Hemacare Corporation - Kaneka Corporation - Kawasumi Laboratories Inc. - Medica S.P.A - Nikkiso Co., Ltd. - Terumo Bct, Inc. - Therakos, Inc. For more information visit http://www.researchandmarkets.com/research/39...sis_market
CERS: 6.08 (+0.05), HAE: 29.44 (+0.36)
HemaCare Reports Strong First Half 2015 Revenue Growth
BusinessWire - Mon Sep 21, 8:00AM CDT
HemaCare Corporation (OTCBB:HEMA) today reported financial results for the six months ended June 30, 2015. For the period, revenue more than doubled to $4.29 million from $2.07 million, gross profit margin percentage improved to 43% from 21%, and loss from operations narrowed to $0.82 million from $2.61 million in the year-earlier period. Reflecting the recent sale of the Company's Therapeutic Apheresis operations, Company total cash as of June 30 was $2.656 million, and there was no outstanding debt. Financial results for the year ended December 31, 2014 are available on the Company's website.
BioLife Solutions Announces HemaCare Will Validate the evo(TM) Smart Shipper and Cloud Based biologistex(TM) Cold Chain Management App
PR Newswire - Thu Sep 17, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced Van Nuys, CA-based HemaCare Corporation (OTCPK:HEMA) will validate BioLife's evo Smart Shipper and biologistex cold chain SaaS. An initial deployment of evo Smart Shippers will be used in transporting Leukopak starting material for CAR-T cellular immunotherapies currently in 3rd party clinical trials in blood cancers and solid tumors.
BLFS: 1.60 (+0.03)
Cryoport Provides Cryogenic Logistics Solutions to HemaCare Corporation
PR Newswire - Thu Jul 30, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company" , the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company will provide cryogenic logistics solutions to HemaCare Corporation ("HemaCare" , a leading global provider of high-quality biological material to the scientific community.
CYRX: 1.63 (-0.07)
Apheresis Equipment - 2015 Global Strategic Business Report: Rising Cancer Incidence to Drive Volume of Apheresis Procedures
M2 - Thu Apr 16, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sjpfd/apheresis) has announced the addition of the "Apheresis Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Apheresis Equipment in US$ Thousands by the following Types: Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global market is analyzed by the following Applications: Erythrocytapheresis, Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 14 companies including many key and niche players such as: - Asahi Kasei Medical Co., Ltd. (Japan) - B Braun Melsungen AG (Germany) - Cerus Corporation (US) - Fresenius Kabi (Germany) - Fenwal, Inc. (US) - Haemonetics Corporation (US) - HemaCare Corp. (US) - Kaneka Corporation (Japan) - Kawasumi Laboratories, Inc. (Japan) - Medica SpA (Italy) - NIKKISO Europe GmbH (Germany) - Terumo BCT, Inc. (US) - Therakos, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. KEY MARKET TRENDS & DRIVERS 3. TECHNOLOGY OVERVIEW 4. BLOOD COMPONENTS & DERIVATIVES 5. PRODUCT DEVELOPMENTS/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 14 (including Divisions/Subsidiaries - 21) - The United States (9) - Japan (3) - Europe (9) - - Germany (6) - - Italy (3) For more information visit http://www.researchandmarkets.com/research/8sjpfd/apheresis
CERS: 6.08 (+0.05), HAE: 29.44 (+0.36)
United States Other Ambulatory Health Care Services Industry Analytics 2014-2021 - Market to Reach $56 Billion by 2021
M2 - Mon Dec 15, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/dph5s9/other_ambulatory) has announced the addition of Plunkett Research Ltd's new report "Other Ambulatory Health Care Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Other Ambulatory Health Care Services Industry (U.S.) to reach $56 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - ActiveCare Inc - Air Methods Corp - American Medical Response Inc - Apollo Medical Holdings Inc - Conmed Healthcare Management Inc - HemaCare Corporation - IPC The Hospitalist Company Inc - InfuSystem Holdings Inc - LogistiCare Solutions LLC - Magellan Health Inc For more information visit http://www.researchandmarkets.com/research/dp...ambulatory Source: Plunkett Research Ltd
AIRM: 36.64 (+0.58), IPCM: 80.17 (+0.01)
HemaCare Attends BIO 2016 and Stem Cell Research Meetings
BusinessWire - Tue May 31, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending two key conferences during the month of June in San Francisco. The first conference, BIO International Convention (BIO), held June 6-9th at the Moscone Center, draws over 15,000 biotechnology and pharma leaders together for a week of intensive networking and partnering to discover new opportunities in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy, a focus critical to HemaCare. The International Society of Stem Cell Research (ISSCR) will be conducted June 22nd-25th, also at the Moscone Center. This meeting is the premiere gathering of research and development scientists, to share and collaborate on advancements in stem cell therapies and treatments. HemaCare is actively expanding its capabilities in support of stem cell research based on increased demand for our portfolio of stem-cell enriched, mobilized peripheral blood and bone marrow-derived primary cells.
HemaCare Attends Cell Therapy Meeting in Singapore
BusinessWire - Mon May 23, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending the ISCT meeting May 25-28th at the Suntec Convention and Exhibit Centre in Singapore, to support the society's annual gathering of clinicians, regulators, researchers and other industry partners, whose objective is to translate cellular therapy into safe and effective treatments to improve patient's lives. This is the first time the ISCT is conducting its annual meeting in Asia, and consequently, there will be added focus on current and future developments of cell therapy delivery and commercialization in Asia, a region where HemaCare has recently expanded through distribution partners. HemaCare will also present a poster session to highlight its core competencies for supplying highly pure and viable human hematopoietic stem cells and mature primary cells in global demand by these investigators.
HemaCare Signs Distribution Agreement with China-Based Partner
BusinessWire - Thu May 12, 3:11PM CDT
HemaCare Corporation, (OTCBB: HEMA) a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in China with Shanghai-based MT-Biological Science and Technology Co. Ltd. This partnership ensures researchers in China can access HemaCare's human healthy and disease state cryopreserved hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support.
HemaCare Attends the American Association of Cancer Research Annual Meeting
BusinessWire - Wed Apr 13, 7:00AM CDT
HemaCare Corporation, (OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending the AACR annual meeting at the Ernest R. Morial Convention Center in New Orleans, Louisiana, to support and learn the latest advances by cancer researchers. The meeting is host to over 16,000 scientific and clinical researchers and patient advocacy groups that focus on translating the mechanisms of cancer pathologies into viable bedside diagnostics and treatments. HemaCare will conduct educational presentations at its booth to increase awareness of its ever expanding capabilities for supplying highly pure and viable human hematopoietic stem cells and mature primary cells in demand by these investigators.
HemaCare Reports Strong 2015 Results
BusinessWire - Mon Apr 11, 7:00AM CDT
HemaCare Corporation, (OTCBB:HEMA) today reported financial results for 2015, showing strong gains in both revenue and gross profit margins compared to the prior year. For the full year, revenue from continuing operations more than doubled to $9.7 million, while gross profit margin rose to 45% from 27%. Loss from continuing operations narrowed to $1.38 million from $4.75 million, and after a gain from the sale of the Company's Therapeutic Apheresis business, 2015 net income totaled $3.24 million.
HemaCare Expands Its Offering of Stem Cell-Enriched Peripheral Blood
BusinessWire - Mon Mar 28, 7:00AM CDT
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it has expanded its offering of stem cell rich peripheral blood through the addition of a new protocol. This type of blood, referred to among researchers as "mobilized peripheral blood," is collected following a procedure that induces the bone marrow to produce more white cells into the periphery. These white cells can then be collected with a routine leukapheresis and provided to researchers within 24 hours. The most widely studied cell populations within these collections are CD34+ stem cells. These cells are used by investigators to study the mechanism of, and develop therapies for, diseases such as cancer, inflammatory conditions like arthritis and immune deficiency-based pathologies such as HIV. Additionally, this type of premium research material is a critical component to advancing research from the bench into potential clinical trials.
HemaCare to Increase Bone Marrow Capability
BusinessWire - Mon Mar 21, 7:00AM CDT
HemaCare Corporation (OTC:HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it has expanded its capabilities to offer stem cell rich bone marrow products by increasing its donor recruitment efforts and internal collection capacity in the Los Angeles, California, area under the direct supervision of its Medical Director. HemaCare's bone marrow portfolio, which includes unprocessed bone marrow, as well as highly purified isolated cell populations, is in high demand globally and a critical component in regenerative medicine research.
HemaCare to Present at Phacilitate Cell & Gene Therapy World 2016
BusinessWire - Wed Jan 13, 1:47PM CST
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, today announced that Lou Juliano, Senior Vice President of Global Sales and Business Development, will present recent findings by HemaCare's research group on the sustainability of freshly isolated leukopaks (apheresis-derived white blood cells) when cryopreserved and shipped around the world for use in cell therapy applications. The results described in this presentation are of key importance to cell therapy researchers, who depend on HemaCare as a source for highly pure, viable, and functional cells to develop their therapies. Additionally, HemaCare will host a roundtable discussion on the importance of donor selection and management when used for the development of allogeneic cell therapies. This discussion will be critical to cell therapy companies who look to develop allogeneic "off-the-shelf" therapies that can treat multiple patients with engineered, cost-effective cancer treatments.
HemaCare Signs Strategic Global Distribution Agreements
BusinessWire - Mon Dec 07, 7:00AM CST
HemaCare Corporation, a leader in cell and tissue collection, processing, and autologous and allogeneic cell therapy solutions, has expanded its global capabilities through strategic distribution agreements in North America, Europe and Asia. These partnerships ensure researchers around the globe can access HemaCare's human healthy and disease state, fresh or frozen, hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local region support.
HemaCare to Support Key Cell Therapy Conferences Through Sponsorship and Technical Presentations
BusinessWire - Mon Nov 02, 7:00AM CST
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, will present at two of the most important meetings in cellular and immune-therapy this month. Each presentation will focus on HemaCare's expertise in preserving hematopoietic cells for use by researchers and developers of immunotherapy.
HemaCare Committed to Cell Therapy Research Through Strategic Agreements
BusinessWire - Mon Oct 19, 7:00AM CDT
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, has expanded its growing cell therapy client portfolio through several supply agreements with Cellectis, Dendreon, and Sotio. Under the agreements, HemaCare provides process development support and supplies high-quality cGMP and research-grade biological material for use in cell therapy research and development of commercially available products, including Provenge(R).
HemaCare to Sponsor Phacilitate Cell & Gene Therapy Meeting Series
BusinessWire - Mon Sep 28, 7:00AM CDT
HemaCare Corporation, a leader in cell and tissue collection, processing and cell therapy solutions, today announced a two-year, multi-event sponsorship of the Phacilitate Cell & Gene Therapy Forums. Considered the largest gathering of cell and gene therapy experts in the world, Cell & Gene Therapy Forums draw leaders from the pharma and biotech communities interested in the latest innovations in cell therapy.
Apheresis (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) Markets Report - Global Forecast to 2020
M2 - Mon Sep 28, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/392dth/apheresis_market) has announced the addition of the "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis), Procedure (Therapeutic Apheresis, Donor Apheresis/Apheresis Blood Donation), Technology & by Product - Global Forecast to 2020" report to their offering. The global apheresis market is expected to reach USD 2.5 Billion by 2020, growing at a CAGR of 11.2% during the forecast period (2015 to 2020) The market is mainly driven by the rising incidences of blood disorders and chronic diseases, increasing demand for source plasma from biopharmaceutical companies, and increasing demand for blood for transfusion in surgical procedures and accident & trauma cases. In this report, the apheresis market is segmented by procedure, product, technology, application, and region. The apheresis market, by procedure, is mainly segmented into automated blood collection and therapeutic apheresis. In 2014, the automated blood collection segment accounted for the largest share of approximately 77.2% of the market, and is expected to grow at a CAGR of 10.7% during the forecast period. Growth in this segment is mainly attributed to the increasing severity of blood shortage and growing concern regarding blood safety, and increasing incidences of blood disorders and chronic diseases. On the basis of applications, the market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, LDL apheresis, and others (photopheresis, lymphapheresis, and extracorporeal immunoadsorption). The plasmapheresis segment accounted for the largest share 46.5% of the global apheresis market in 2014. The large share of plasmapheresis is attributed to the increasing demand of source plasma for transfusion from hospitals and for fractionation from biopharmaceutical companies. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Apheresis Market, By Procedure 8 Global Apheresis Market, By Product 9 Global Apheresis Market, By Technology 10 Global Apheresis Market, By Application 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Group) - B. Braun Melsungen AG - Cerus Corporation - Fresenius Se & Co. KGAA - Haemonetics Corporation - Hemacare Corporation - Kaneka Corporation - Kawasumi Laboratories Inc. - Medica S.P.A - Nikkiso Co., Ltd. - Terumo Bct, Inc. - Therakos, Inc. For more information visit http://www.researchandmarkets.com/research/39...sis_market
CERS: 6.08 (+0.05), HAE: 29.44 (+0.36)
HemaCare Reports Strong First Half 2015 Revenue Growth
BusinessWire - Mon Sep 21, 8:00AM CDT
HemaCare Corporation (OTCBB:HEMA) today reported financial results for the six months ended June 30, 2015. For the period, revenue more than doubled to $4.29 million from $2.07 million, gross profit margin percentage improved to 43% from 21%, and loss from operations narrowed to $0.82 million from $2.61 million in the year-earlier period. Reflecting the recent sale of the Company's Therapeutic Apheresis operations, Company total cash as of June 30 was $2.656 million, and there was no outstanding debt. Financial results for the year ended December 31, 2014 are available on the Company's website.
BioLife Solutions Announces HemaCare Will Validate the evo(TM) Smart Shipper and Cloud Based biologistex(TM) Cold Chain Management App
PR Newswire - Thu Sep 17, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced Van Nuys, CA-based HemaCare Corporation (OTCPK:HEMA) will validate BioLife's evo Smart Shipper and biologistex cold chain SaaS. An initial deployment of evo Smart Shippers will be used in transporting Leukopak starting material for CAR-T cellular immunotherapies currently in 3rd party clinical trials in blood cancers and solid tumors. BLFS: 1.60 (+0.03)
Cryoport Provides Cryogenic Logistics Solutions to HemaCare Corporation
PR Newswire - Thu Jul 30, 7:30AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"
, the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company will provide cryogenic logistics solutions to HemaCare Corporation ("HemaCare" , a leading global provider of high-quality biological material to the scientific community. CYRX: 1.63 (-0.07)
Apheresis Equipment - 2015 Global Strategic Business Report: Rising Cancer Incidence to Drive Volume of Apheresis Procedures
M2 - Thu Apr 16, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sjpfd/apheresis) has announced the addition of the "Apheresis Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Apheresis Equipment in US$ Thousands by the following Types: Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global market is analyzed by the following Applications: Erythrocytapheresis, Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 14 companies including many key and niche players such as: - Asahi Kasei Medical Co., Ltd. (Japan) - B Braun Melsungen AG (Germany) - Cerus Corporation (US) - Fresenius Kabi (Germany) - Fenwal, Inc. (US) - Haemonetics Corporation (US) - HemaCare Corp. (US) - Kaneka Corporation (Japan) - Kawasumi Laboratories, Inc. (Japan) - Medica SpA (Italy) - NIKKISO Europe GmbH (Germany) - Terumo BCT, Inc. (US) - Therakos, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. KEY MARKET TRENDS & DRIVERS 3. TECHNOLOGY OVERVIEW 4. BLOOD COMPONENTS & DERIVATIVES 5. PRODUCT DEVELOPMENTS/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 14 (including Divisions/Subsidiaries - 21) - The United States (9) - Japan (3) - Europe (9) - - Germany (6) - - Italy (3) For more information visit http://www.researchandmarkets.com/research/8sjpfd/apheresis
CERS: 6.08 (+0.05), HAE: 29.44 (+0.36)
United States Other Ambulatory Health Care Services Industry Analytics 2014-2021 - Market to Reach $56 Billion by 2021
M2 - Mon Dec 15, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/dph5s9/other_ambulatory) has announced the addition of Plunkett Research Ltd's new report "Other Ambulatory Health Care Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Other Ambulatory Health Care Services Industry (U.S.) to reach $56 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - ActiveCare Inc - Air Methods Corp - American Medical Response Inc - Apollo Medical Holdings Inc - Conmed Healthcare Management Inc - HemaCare Corporation - IPC The Hospitalist Company Inc - InfuSystem Holdings Inc - LogistiCare Solutions LLC - Magellan Health Inc For more information visit http://www.researchandmarkets.com/research/dp...ambulatory Source: Plunkett Research Ltd
AIRM: 36.64 (+0.58), IPCM: 80.17 (+0.01)
(0)
(0)